CN102847050A - A Chinese medicinal effective fraction composition for treating depression - Google Patents
A Chinese medicinal effective fraction composition for treating depression Download PDFInfo
- Publication number
- CN102847050A CN102847050A CN2011101756050A CN201110175605A CN102847050A CN 102847050 A CN102847050 A CN 102847050A CN 2011101756050 A CN2011101756050 A CN 2011101756050A CN 201110175605 A CN201110175605 A CN 201110175605A CN 102847050 A CN102847050 A CN 102847050A
- Authority
- CN
- China
- Prior art keywords
- depression
- herba hyperici
- chinese medicinal
- curcumin
- radix ginseng
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 78
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims abstract description 62
- 235000008434 ginseng Nutrition 0.000 claims abstract description 37
- 235000012754 curcumin Nutrition 0.000 claims abstract description 35
- 239000003814 drug Substances 0.000 claims abstract description 32
- 229940109262 curcumin Drugs 0.000 claims abstract description 31
- 239000004148 curcumin Substances 0.000 claims abstract description 31
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 claims abstract description 31
- 238000002360 preparation method Methods 0.000 claims abstract description 30
- 239000000284 extract Substances 0.000 claims abstract description 11
- 239000008187 granular material Substances 0.000 claims abstract description 9
- 239000007901 soft capsule Substances 0.000 claims abstract description 8
- 239000002775 capsule Substances 0.000 claims abstract description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 72
- 241000208340 Araliaceae Species 0.000 claims description 37
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 36
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 36
- 229930003944 flavone Natural products 0.000 claims description 33
- 150000002213 flavones Chemical class 0.000 claims description 33
- 235000011949 flavones Nutrition 0.000 claims description 33
- 235000017709 saponins Nutrition 0.000 claims description 31
- 229930182490 saponin Natural products 0.000 claims description 30
- 150000007949 saponins Chemical class 0.000 claims description 30
- 238000000034 method Methods 0.000 claims description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 229940079593 drug Drugs 0.000 claims description 12
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 10
- 239000003826 tablet Substances 0.000 claims description 10
- 208000020401 Depressive disease Diseases 0.000 claims description 8
- 238000001035 drying Methods 0.000 claims description 8
- 239000006187 pill Substances 0.000 claims description 7
- 239000007919 dispersible tablet Substances 0.000 claims description 5
- 210000000214 mouth Anatomy 0.000 claims description 5
- 238000010992 reflux Methods 0.000 claims description 5
- 239000003463 adsorbent Substances 0.000 claims description 4
- 238000010828 elution Methods 0.000 claims description 4
- 239000012567 medical material Substances 0.000 claims description 4
- 239000011347 resin Substances 0.000 claims description 4
- 229920005989 resin Polymers 0.000 claims description 4
- 238000002425 crystallisation Methods 0.000 claims description 2
- 230000008025 crystallization Effects 0.000 claims description 2
- 235000020241 curcumin extract Nutrition 0.000 claims description 2
- 239000006196 drop Substances 0.000 claims description 2
- 238000000605 extraction Methods 0.000 claims description 2
- 238000010521 absorption reaction Methods 0.000 claims 3
- 238000003795 desorption Methods 0.000 claims 3
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000000469 ethanolic extract Substances 0.000 claims 1
- 239000006186 oral dosage form Substances 0.000 claims 1
- 239000002552 dosage form Substances 0.000 abstract description 6
- 230000009471 action Effects 0.000 abstract description 4
- 230000000144 pharmacologic effect Effects 0.000 abstract description 4
- 238000011160 research Methods 0.000 abstract description 4
- 238000009472 formulation Methods 0.000 abstract description 2
- 239000004615 ingredient Substances 0.000 abstract description 2
- 244000141009 Hypericum perforatum Species 0.000 abstract 2
- 235000017309 Hypericum perforatum Nutrition 0.000 abstract 2
- 210000004185 liver Anatomy 0.000 abstract 2
- 240000004371 Panax ginseng Species 0.000 abstract 1
- 235000002789 Panax ginseng Nutrition 0.000 abstract 1
- 230000000994 depressogenic effect Effects 0.000 abstract 1
- 229930003935 flavonoid Natural products 0.000 abstract 1
- 150000002215 flavonoids Chemical class 0.000 abstract 1
- 235000017173 flavonoids Nutrition 0.000 abstract 1
- 229940089161 ginsenoside Drugs 0.000 abstract 1
- 229930182494 ginsenoside Natural products 0.000 abstract 1
- 239000007902 hard capsule Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000003340 mental effect Effects 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
- 239000008513 turmeric extract Substances 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 description 21
- 239000000243 solution Substances 0.000 description 16
- 239000008194 pharmaceutical composition Substances 0.000 description 14
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 11
- LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 11
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 11
- BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 11
- 229960003147 reserpine Drugs 0.000 description 11
- MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- 238000010172 mouse model Methods 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 9
- 230000006698 induction Effects 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 239000013558 reference substance Substances 0.000 description 8
- 230000001430 anti-depressive effect Effects 0.000 description 7
- 239000000935 antidepressant agent Substances 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 230000009182 swimming Effects 0.000 description 7
- 229940005513 antidepressants Drugs 0.000 description 6
- 239000012467 final product Substances 0.000 description 6
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 229960002464 fluoxetine Drugs 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 210000000744 eyelid Anatomy 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 206010010144 Completed suicide Diseases 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 229930182470 glycoside Natural products 0.000 description 3
- 150000002338 glycosides Chemical class 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- RTHCYVBBDHJXIQ-UHFFFAOYSA-N N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine Chemical group C=1C=CC=CC=1C(CCNC)OC1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000007963 capsule composition Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 2
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 2
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 2
- 235000005493 rutin Nutrition 0.000 description 2
- 229960004555 rutoside Drugs 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- 101100433727 Caenorhabditis elegans got-1.2 gene Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 208000027534 Emotional disease Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- OVSQVDMCBVZWGM-SJWGPRHPSA-N Hyperin Natural products O[C@H]1[C@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-SJWGPRHPSA-N 0.000 description 1
- FVQOMEDMFUMIMO-UHFFFAOYSA-N Hyperosid Natural products OC1C(O)C(O)C(CO)OC1OC1C(=O)C2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 FVQOMEDMFUMIMO-UHFFFAOYSA-N 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000000049 anti-anxiety effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000020710 ginseng extract Nutrition 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 239000004518 granules dosage form Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 208000024714 major depressive disease Diseases 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 238000005375 photometry Methods 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- OVSQVDMCBVZWGM-DTGCRPNFSA-N quercetin 3-O-beta-D-galactopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-DTGCRPNFSA-N 0.000 description 1
- BBFYUPYFXSSMNV-UHFFFAOYSA-N quercetin-7-o-galactoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=C2C(=O)C(O)=C(C=3C=C(O)C(O)=CC=3)OC2=C1 BBFYUPYFXSSMNV-UHFFFAOYSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- -1 reflux Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000011003 system suitability test Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention discloses a Chinese medicinal effective fraction composition for treating depression, comprising Hypericum perforatum extract containing Hypericum perforatum total flavonoids as effective fraction, Curcuma longa extract containing curcumin as effective fraction, and Panax ginseng extract containing ginsenoside as effective fraction. The invention can utilize the compatibility of the ingredients to treat depression, take multi-link, multi-path, multi-target action in soothing the liver, relieving the depressed liver, and relieving mental stress. The composition may be in the medically acceptable solid oral preparation in dosage form of such as tablet, capsule (soft capsule or hard capsule) and granule. Pharmacological research on effective fractions extracted from the formulation shows that the medicine has specific inhibitory effect on multiple depression models.
Description
Technical field
The invention belongs to medical technical field, relate to a kind of medicine of Cure of depression, the Chinese medicinal effective-part composition that is specifically formed by Herba Hyperici perforati total flavones, Radix Ginseng total saponins, curcumin.
Background technology
Depression is a kind of common emotion and mental disorder disease, and along with the quickening of social life rhythm, depression has become the disease occurred frequently of society.World Health Organization's statistics in 2005, the prevalence of various depressions accounts for 11% of population in the world.Show that according to China's Epidemiological study in 2003 China has 3,600 ten thousand patients with depression at least, wherein only has 5% severe patient to accept associated treatment.Many major depression patients are arranged because in time not carrying out the regular treatment committed suicide.According to death toll in 2003 according to one's analysis, China has 28.7 ten thousand population committed suicides every year at least.Suicide is the 5th cause of the death in the population of China, is first cause of the death of 15～34 years old crowd.Therefore, the drug research of reinforcement Cure of depression has important society and economic implications.
At present the pharmacology attribute of the antidepressants in the Western medicine mainly be heavily absorb with monoamine transmitters or metabolic inhibition relevant, research data shows, it may not be to cause the topmost Pathophysiology reason of depression that Monoamines lacks, though and the Western medicine curative effect certainly, have that toxic and side effects is large, antidepressant spectrum narrow, easy recurrence, medicine valency and dependency high; The Chinese medicine depression is based on integrally-regulated, have good effect, side effect little, be fit to long-term taking and many advantages such as safe and reliable.Both at home and abroad more and more paying attention to traditional drugs aspect the development of antidepressants and the exploitation, even American-European countries is also with the main force medicine of true medicable traditional drugs as Cure of depression.The relevant expert thinks, domestic pharmaceutical manufacturer should be placed on development Traditional Chinese Medicine Anti depressant drug aspect to research and development centre, and the development of Chinese medicine new antidepressant is just at the early-stage, and existing kind all exists prescription complicated on the market, and drug effect and standard substance are inaccurate, quality controllability is not high, the drawbacks such as effective substance is indefinite, and a day dose causes greatly patient dependence bad, and the antidepressant curative effect is not remarkable, the depth ﹠ wideth of antidepressant research all remains further to be improved, and the market development potential is huge.
Along with the limitation of Western medicine is familiar with by people and the change of world's spectrum of disease and medical model gradually, advocating natural drug is just becoming a kind of worldwide trend, and Chinese Medicine Industry is faced with unprecedented opportunities.But, the low inferior reason of level of modernization owing to the Chinese medicine industry, the problems such as Chinese Medicine Industry ubiquity production technology backwardness, unstable product quality, scientific and technological content are low cause a little less than the competitiveness in the international market of Chinese Medicine Industry, and Chinese Medicine Industry is faced with stern challenge.Compound preparation is the characteristic of Chinese medicine clinical practice, also is the principal mode of Chinese medicine preparation.It is substantially clear and definite that Chinese medicinal effective-part composition has effective substance, the mechanism of action is relatively clear, clinical adaptation disease is more definite, and stronger specific aim arranged, safe and effective, adapting to the Technology of modern manufacturing industry and the advantage of quality standard, is the novel modern Chinese medicine that possesses " triple effect " (efficient, quick-acting, long-acting), " three is little " (dosage, toxicity, side effect are little), " three just " (store, carry, taking convenience) characteristics.
There is no at present anti-anxiety compound effective site Chinese medicine and come out, and the Herba Hyperici perforati total flavones take effective site as main active, Radix Ginseng total saponins, the antidepressant effect of curcumin are respectively given priority to from different, have clinically the great demand of drug combination.Therefore, provide effective substance substantially clear and definite, the mechanism of action is relatively clear, and clinical adaptation disease specific aim is stronger, safe and effective, adapts to the Technology of modern manufacturing industry and the Chinese traditional effective part compound preparation of quality standard and has important clinical meaning.With the patent of having declared as the inventor (application number 201010101856.X) relatively, the present invention has that effective substance is substantially clear and definite, taking dose reduces, drug effect is stronger, quality is more controlled, has the Technology and the quality standard that adapt to modern manufacturing industry.
Summary of the invention
The purpose of this invention is to provide a kind of Chinese medicinal effective-part composition that is used for the treatment of depression, its effective substance is substantially clear and definite, and is quality controllable, and can dispersing the stagnated live-QI to relieve the stagnation of QI, mind tranquilizing and the heart calming, produce synergism, raising evident in efficacy.The present invention aims to provide a kind of clinically better efficacy, more easily effective ingredient in Chinese compound and preparation thereof.
Compared with prior art, the invention has the beneficial effects as follows: this pharmaceutical composition contains Herba Hyperici perforati total flavones, Radix Ginseng total saponins, curcumin, produces collaborative antidepressant effect, proves that through pharmacodynamics test it is evident in efficacy.
The present invention is implemented by following technical proposals.
Medicine of the present invention raw materials used weight proportion can be Herba Hyperici perforati total flavones 0.5-1.5 part, Radix Ginseng total saponins 0.2-1 part, curcumin 0.5-2 part.
Pharmaceutical dosage form of the present invention can be the oral formulations such as tablet, drop pill, capsule, soft capsule, granule, and adjuvant is the corresponding adjuvant of acceptable on the pharmaceutics.
The used Herba Hyperici perforati total flavones purity of the present invention is not less than 50%, and Radix Ginseng total saponins purity is not less than 50%, and curcumin purity is not less than 50%.
In the pharmaceutical composition of Cure of depression of the present invention, described Herba Hyperici perforati total flavones extracts from Herba Hyperici perforati, and Radix Ginseng total saponins extracts from Radix Ginseng, and curcumin extracts from Rhizoma Curcumae Longae; The content of described Herba Hyperici perforati total flavones, Radix Ginseng total saponins, curcumin all meets above-mentioned requirements.
Effective site in the said composition is available literature method preparation all, also can buy from market, can also oneself prepare.
Described Herba Hyperici perforati total flavones can be with the preparation of following method: the Herba Hyperici perforati medical material is cut into long section, with 60% alcohol reflux 2 times, adds 12 times of amount 60% soak with ethanol for the first time and spend the night after (12 hours) reflux, extract, 1.5h; Add for the second time 8 times of 60% ethanol, reflux, extract, 1h.Merge extractive liquid,, filter, filtrate is concentrated into 0.2～0.8g (raw medicinal herbs)/ml, adds the D101 macroporous adsorbent resin of having handled well, washes with water first except the impurity such as saccharide react to molish to be negative, then use 3～4 times of volume 40% ethanol elutions, collect eluent, concentrating under reduced pressure, vacuum drying is to constant weight, namely get Herba Hyperici perforati total flavones content greater than 50%, wherein the content of Herba Hyperici Monogyni glycosides is not less than 20%.The assay of above-mentioned Herba Hyperici perforati total flavones (ultraviolet-visible light photometry)
The preparation of reference substance solution: precision takes by weighing 120, and " C is dried to the control substance of Rutin 25mg of constant weight, puts in the 50ml measuring bottle, adds appropriate amount of ethanol, and supersound process makes dissolving, lets cool, and adds ethanol dilution to scale, shakes up.Precision is measured mentioned solution 20ml, puts in the 50ml measuring bottle, is diluted with water to scale, shakes up, and namely gets (every 1ml contains rutin 0.20mg).
The preparation of need testing solution: get this product powder 0.5g, accurately weighed, put in the 100ml tool plug conical flask, accurate 50% ethanol 50ml, weighed weight, the supersound process 15 minutes of adding, be cooled to room temperature, weighed weight is supplied the weight that subtracts mistake with 50% ethanol again, filter, precision is measured subsequent filtrate 1ml and is put in the 10ml measuring bottle, with 50% ethanol dilution to scale, shake up, filter, get subsequent filtrate, and get final product.
Algoscopy: get respectively reference substance and need testing solution, take solvent as blank, according to ultraviolet visible spectrophotometry (appendix VA of Chinese Pharmacopoeia version in 2010), measure trap at 500nm wavelength place, calculate and get final product.
The assay of above-mentioned Herba Hyperici Monogyni glycosides (high-efficient liquid phase technique)
Chromatographic condition and system suitability test: take octadecylsilane silica gel as filler; Take acetonitrile-0.1% phosphoric acid solution (16: 84) as mobile phase; The detection wavelength is 360nm.Number of theoretical plate calculates by the hyperin peak should be not less than 3000.
The preparation of reference substance solution: it is an amount of that precision takes by weighing Herba Hyperici Monogyni glycosides reference substance, adds methanol and make the solution that every 1mL contains 0.25mg, and get final product.
The preparation of need testing solution: get 2 of this product, porphyrize is got the about 0.2g of powder, and is accurately weighed, puts in the tool plug conical flask, the accurate 60% ethanol 100ml that adds, weighed weight, supersound process 15min is cooled to room temperature, more weighed weight, supply with 60% ethanol and to subtract weight loss, shake up, filter, and get final product.
Algoscopy: precision is drawn reference substance and each 5 μ l of need testing solution respectively, and the injection liquid chromatography is measured.
Curcumin in the present composition can prepare with following method: wherein said curcumin prepares by the following method: the Rhizoma Curcumae Longae pulverizing medicinal materials is become coarse powder, adopt the SFE-C02 extraction, or different concentration ethanol is extracted, the extracting solution Recycled ethanol, be concentrated into extractum again after the ungrease treatment acetone reflux, collect acetone solution, be concentrated into extractum and carry out again crystallization treatment, cold drying namely gets content greater than 50% curcumin.
The assay of above-mentioned curcumin (high-efficient liquid phase technique)
Chromatographic condition and system suitability: take octadecylsilane silica gel as filler; Take acetonitrile-4% glacial acetic acid solution (48: 52) as mobile phase; The detection wavelength is 430nm.Number of theoretical plate calculates by the curcumin peak should be not less than 4000.
The preparation of reference substance solution: it is an amount of that precision takes by weighing the curcumin reference substance, adds methanol and make the solution that every 1mL contains 0.25mg, and get final product.
The preparation of need testing solution: get 2 of this product, porphyrize is got the about 0.2g of powder, and is accurately weighed, puts in the tool plug conical flask, the accurate methanol 50ml that adds, weighed weight, supersound process 15min is cooled to room temperature, more weighed weight, supply with methanol and to subtract weight loss, shake up, filter, and get final product.
Algoscopy: precision is drawn reference substance and each 5 μ l of need testing solution respectively, and the injection liquid chromatography is measured.
Radix Ginseng total saponins in the present composition can adopt the commercial goods of direct purchase, and the product of purchase must meet national standard.
Another object of the present invention has provided the preparation method of pharmaceutical composition of the present invention, and the method can adopt the conventional method of pharmaceutical field, uses conventional pharmaceutic adjuvant to carry out.After for example adopting conventional method that Herba Hyperici perforati total flavones, Radix Ginseng total saponins, curcumin are evenly mixed, mix with carrier or adjuvant commonly used on any one or more than one pharmaceutics, then make various peroral dosage forms.Described carrier such as excipient, filler, diluent, lubricant, wetting agent, disintegrating agent, surfactant, antiseptic, sweeting agent, aromatic etc.Particularly, described carrier such as starch, dextrin, lactose, microcrystalline Cellulose, hydroxypropyl methylcellulose, Polyethylene Glycol, magnesium stearate, micropowder silica gel, glucose, mannitol, xylitol, glycine etc.
As required, pharmaceutical composition of the present invention can be made into the preparation that is suitable for oral medication, can be following arbitrary dosage form: tablet, capsule, soft capsule, granule, drop pill, dispersible tablet, oral cavity disintegration tablet, pill.
Another object of the present invention has provided pharmaceutical composition of the present invention in the application of Cure of depression.
The specific embodiment
For the present invention is further described in detail, provide specific embodiment, but only the present invention is illustrated in conduct, rather than in order to limit the scope of the invention.
Granule, tablet or the capsule formulation of embodiment 1 pharmaceutical composition of the present invention
The preparation of granule: adopt conventional preparation granule technique, get 0.5 part of Herba Hyperici perforati total flavones, 1 part of Radix Ginseng total saponins, 0.5 part of curcumin, right amount of auxiliary materials.Mixing is granulated, and sieves, and drying makes the pharmaceutical composition of granule dosage form.
The preparation of tablet: through further tabletting, drying namely makes the pharmaceutical composition of the Tabules that contains 0.5 part of Herba Hyperici perforati total flavones, 1 part of Radix Ginseng total saponins, 0.5 part of curcumin with the granule that makes.
The preparation of capsule: the granule that makes is incapsulated shell, make capsule, namely make the pharmaceutical composition of the capsule formulation that contains 0.5 part of Herba Hyperici perforati total flavones, 1 part of Radix Ginseng total saponins, 0.5 part of curcumin.
The drops of embodiment 2 present compositions
Preparation: adopt the technique of conventional preparation drop pill, get 1 part of Herba Hyperici perforati total flavones, 0.5 part of Radix Ginseng total saponins, 1 part of curcumin, right amount of auxiliary materials makes the drop pill of this pharmaceutical composition.
The soft capsule dosage form of embodiment 3 present compositions
Preparation: adopt the technique of conventional preparation soft capsule, get 1.5 parts of Herba Hyperici perforati total flavones, 1 part of Radix Ginseng total saponins, 2 parts of curcumins, right amount of auxiliary materials, mixing is made capsule casing material with gelatin, is pressed into soft capsule, makes the soft capsule of this pharmaceutical composition.
The micropill dosage form of embodiment 4 present compositions
Preparation: adopt the technique of conventional preparation micropill, get 1.2 parts of Herba Hyperici perforati total flavones, 0.8 part of Radix Ginseng total saponins, 1.5 parts of curcumins, right amount of auxiliary materials makes the micropill of this pharmaceutical composition.
The oral cavity disintegration tablet of embodiment 5 present compositions
Preparation: adopt the technique of conventional preparation oral cavity disintegration tablet, get 1 part of Herba Hyperici perforati total flavones, 1 part of Radix Ginseng total saponins, 1 part of curcumin, right amount of auxiliary materials makes the oral cavity disintegration tablet of this pharmaceutical composition.
The dispersible tablet of embodiment 6 present compositions
Preparation: adopt the technique of conventional preparation dispersible tablet, get 1.5 parts of Herba Hyperici perforati total flavones, 0.5 part of Radix Ginseng total saponins, 2 parts of curcumins, right amount of auxiliary materials makes the dispersible tablet of this pharmaceutical composition.
The test of pesticide effectiveness of embodiment 9 present compositions
The purpose of this test is to observe the present composition to the therapeutical effect of depression model mice.Present composition A, B, C all adopt extractum, and the time spent is prepared desired concn with pure water, the favourable Xueping injection of other reagent chemicalses, and 1mg/ml, lot number: 081017 people pharmaceutical Co. Ltd of Guangdong nation produces.Fluoxetine, specification 20mg/ sheet, lot number: A509291, Lilly S.A produces.
Compositions A: get 0.5 part of Herba Hyperici perforati total flavones, 1.5 parts of Radix Ginseng total saponinss, 2 parts of curcumins.
Compositions B: get 1 part of Herba Hyperici perforati total flavones, 1 part of Radix Ginseng total saponins, 0.5 part of curcumin.
Compositions C: get 1.5 parts of Herba Hyperici perforati total flavones, 0.2 part of Radix Ginseng total saponins, 1 part of curcumin.
Compositions D: namely declared patent 201010101856.X, Rhizoma Curcumae Longae, Herba Hyperici perforati, ginseng composition are got 1 part in Rhizoma Curcumae Longae, 1 part of Herba Hyperici perforati, 1 part of Radix Ginseng, add 50% soak with ethanol and extract 2 times after 0.5 hour, amount of water is respectively 8 times, 6 times, extracted 2 hours for the first time, extracted 1 hour for the second time, filter, merging filtrate, concentrated, drying gets compositions D dry extract after the pulverizing.
1, on the impact of acquired desperate model mice
1) on the impact of outstanding tail dead time of acquired desperate model mice
Get 90 of ♂ ICR mices, SPF level, body weight 18-22g, be divided at random 6 groups, 15 every group: i.e. model group, prozac group, compositions A group, compositions B group, compositions C group, compositions D group, ig administration volume 20ml/kg, every day 1 time, each is organized mice and gives respectively relative medicine, model group gives with the volume distilled water, successive administration 7 days.30min after the last administration is fixed in the mice inversion on the outstanding tail apparatus, and head records the dead time of rear 4min in the 6min apart from the about 10cm of desktop.Hang both sides and separate the animal sight line with plate, influence each other preventing.The results are shown in Table 1.
Table 1 on the impact of mouse tail suspension dead time (
N=15, S)
Annotate: compare with model group
*P＜0.05,
*P＜0.01; Compare with compositions D,
#P＜0.05,
##P＜0.01.
As known from Table 1, compare with model group, the outstanding tail dead time of fluoxetine treated animal reduces (P＜0.05); Compositions A, B, C, outstanding tail dead time of D treated animal reduce (P＜0.05 or P＜0.01).Compare compositions A, B, the outstanding obvious time decreased of tail dead time (P＜0.05) of C treated animal with compositions D.Prompting, the pharmacological action of compositions A, B, C is better than compositions D.
2) on the impact of mice forced swimming dead time
Grouping is the same with administration.1h after the last administration, mice is individually put into the beaker of depth of water 10cm, water temperature (25 ± 2) ℃ forced swimming, observe 6min, keep the motionless state time (s) in the 4min behind the record, the fixed finger mice stops to struggle in water, or floating state, small limb activity is only arranged to keep head to keep afloat.The results are shown in Table 2.
Table 2 on the impact of mice forced swimming dead time (
N=15, s)
Annotate: compare with model group
*P＜0.05,
*P＜0.01.
As known from Table 2, compare with model group, fluoxetine treated animal non-swimming time shortens (P＜0.01); Compositions A, B, C, D treated animal non-swimming time shorten (P＜0.05 or P＜0.01).Compare compositions A, B, the outstanding obvious time decreased of tail dead time (P＜0.05) of C treated animal with compositions D.Prompting, the pharmacological action of compositions A, B, C is better than compositions D.
2, on the impact of the depression model mice of reserpine induction
(1) on the depression model mice behavior of reserpine induction and the impact of body temperature
1) on the depression model mice lapsus palpebrae superioris of reserpine induction and motion can not behavior impact
Get ♂ ICR mice, SPF level, 120, body weight 18-22g is divided into 6 groups at random, 20 every group: namely blank is organized, model group, prozac group, compositions A group, compositions B group, compositions C group, compositions D group, ig administration volume 20ml/kg, every day 1 time, each is organized mice and gives respectively relative medicine, blank group gives with the volume distilled water successive administration 18 days with model group.Lumbar injection reserpine 4mg/kg in the time of administration in the 15th day, 1h, 2h, 6h are put in animal the number of animals that eye alkali is closed in each group of observation on the support behind the injection reserpine, and eye alkali closed and closes the difference degree of grade between relatively each was organized with rank test.And after to reserpine 2h, 4h, 6h, place the circular in vain finger of diameter 7.5cm central animal, and observed 15 seconds, record each treated animal and still stayed in the interior number of animals of circle in 15 seconds, and carry out statistical procedures.The results are shown in Table 3.
Table 3 on the impact of the depression model mice catacleisis degree of reserpine induction (
N=20)
Annotate: compare with model group,
*P＜0.05,
*P＜0.01; Compare with compositions D,
#P＜0.05,
##P＜0.01.
As known from Table 3, with model group relatively, after the administration of fluoxetine group 1,2, the 6h animal eyelid degree of closing significantly reduces (P＜0.05); The degree that 1h animal eyelid is closed after the compositions D administration significantly reduces (P＜0.05); After the administration of compositions A, B, C group 1,2, the 6h animal eyelid degree of closing significantly reduces (P＜0.05).Compare with compositions D, the degree that 6h animal eyelid is closed after compositions A, B, the administration of C group significantly reduces (P＜0.05 or P＜0.01).Prompting, compositions A, B, C have the effect of the depression model mice catacleisis degree that reduces reserpine induction; Compare with compositions D, compositions A, B, C have strong drug action, the long characteristics of holding time.
Table 4 on depression model mice zero paper of reserpine induction go too far rate impact (
N=20)
Annotate: compare with the blank group,
▲P＜0.05,
▲ ▲P＜0.01; Compare with model group
*P＜0.05,
*P＜0.01; Compare with compositions D,
#P＜0.05,
##P＜0.01.
As known from Table 4, with the blank group relatively, the model group animal zero paper rate (2h, 4h, 6h behind the medicine) that goes too far significantly reduces (P＜0.01), shows the modeling success.With model group relatively, the fluoxetine group behind medicine 2, the 4h rate number of animals that goes too far significantly increases, through X
2Check difference has statistical significance (P＜0.05 or P＜0.01); Compositions D organizes in 2h, the 4h zero paper number of animals that goes too far significantly to be increased, through X
2Check difference has statistical significance (P＜0.05 or P＜0.01); Compositions A, B, C organize in 2h, 4h, the 6h zero paper number of animals that goes too far significantly increases (P＜0.01 or P＜0.05).With compositions D relatively, the 6h zero paper number of animals that goes too far significantly increases (P＜0.05) after compositions A, B, the administration of C group.Prompting, compositions A, B, C, D have the go too far effect of rate of depression model mice zero paper that increases reserpine induction; Compare with compositions D, compositions A, B, C have the long characteristics of duration of efficacy.
Pharmacological tests shows that the present invention significantly depression model mouse movement of antagonism reserpine induction can not reach the body temperature reduction, and desperate animal model autonomic activities number, outstanding tail and non-swimming time that outstanding tail and forced swimming are induced increase.Prompting the present invention has obvious antidepressant effect, and has the long characteristics of duration of efficacy.
Claims (14)
1. Chinese medicinal effective-part composition that is used for the treatment of depression, it is characterized in that: it includes Herba Hyperici perforati total flavones, Radix Ginseng total saponins, curcumin effective site.
2. Chinese medicinal effective-part composition that is used for the treatment of depression, it is characterized in that: it is comprised of Herba Hyperici perforati total flavones, Radix Ginseng total saponins, curcumin active ingredient group, and its weight proportion is Herba Hyperici perforati total flavones 0.5-5 part, Radix Ginseng total saponins 0.2-5 part, curcumin 0.5-4 part.
3. the Chinese medicinal effective-part composition of claim 1, wherein the weight proportion of each effective site is: Herba Hyperici perforati total flavones 0.5-1.5 part, Radix Ginseng total saponins 0.2-1.5 part, curcumin 0.5-2 part
4. the Chinese medicinal effective-part composition that is used for the treatment of depression claimed in claim 1, the purity of wherein said Herba Hyperici perforati total flavones is for being not less than 50%.
5. the Chinese medicinal effective-part composition that is used for the treatment of depression claimed in claim 1, the purity of wherein said Radix Ginseng total saponins is not less than 50%.
6. the Chinese medicine composition that is used for the treatment of depression claimed in claim 1, the purity of wherein said curcumin is not less than 50%.
7. the Chinese medicinal effective-part composition of the described Cure of depression of claim 1-6 any one, wherein Herba Hyperici perforati total flavones extracts from Herba Hyperici perforati, described Radix Ginseng total saponins extracts from Radix Ginseng, and described curcumin extracts from Rhizoma Curcumae Longae.
8. the Chinese medicinal effective-part composition of the described Cure of depression of claim 7, wherein said Herba Hyperici perforati total flavones prepares by the following method: Herba Hyperici perforati medical material water or different concentration ethanol are extracted, the extracting solution Recycled ethanol is concentrated into proper volume; The concentrated solution absorption with macroporous adsorbent resin washes with water first to effluent colourlessly, uses the low-concentration ethanol desorption again, collects ethanol elution, Recycled ethanol, and drying namely gets Herba Hyperici perforati total flavones.
9. the Chinese medicinal effective-part composition of the described Cure of depression of claim 7, wherein said Radix Ginseng total saponins prepares by the following method: adopt water or different concentration ethanol to extract the ginseng crude drug, the extracting solution Recycled ethanol is concentrated into proper volume; The concentrated solution absorption with macroporous adsorbent resin washes with water first to effluent colourlessly, uses the low-concentration ethanol desorption again, collects ethanol elution, Recycled ethanol, and drying namely gets Radix Ginseng total saponins.
10. the Chinese medicinal effective-part composition of the described Cure of depression of claim 7, wherein said curcumin prepares by the following method: the Rhizoma Curcumae Longae medical material is adopted SFE-CO
2Extraction, or different concentration ethanol extracts, the extracting solution Recycled ethanol, be concentrated into extractum again after the ungrease treatment acetone reflux, collect acetone solution, be concentrated into extractum and carry out again crystallization treatment, cold drying namely gets content greater than 50% curcumin.
11. the Chinese medicinal effective-part composition of the described Cure of depression of claim 7, wherein said Herba Hyperici perforati total flavones, Radix Ginseng total saponins, curcumin prepare by the following method: adopt different concentration ethanol to extract Herba Hyperici perforati, Radix Ginseng, Rhizoma Curcumae Longae medical material, the extracting solution Recycled ethanol is concentrated into proper volume; The concentrated solution absorption with macroporous adsorbent resin, wash with water first to effluent colourless, use again the low-concentration ethanol desorption, collect ethanol elution, Recycled ethanol, drying, namely get Herba Hyperici perforati total flavones purity greater than 50%, Radix Ginseng total saponins purity greater than 50%, curcumin purity is greater than 50% effective site group extract.
12. the Chinese medicinal effective-part composition of described Cure of depression according to claim 1-11, wherein said composition weight ratio is: Herba Hyperici perforati total flavones 0.5-1.5 part, Radix Ginseng total saponins 1-2 part, curcumin 0.5-2 part.
13. the Chinese medicinal effective-part composition of the described Cure of depression of any one according to claim 1-12, said composition is made into to be fit to oral dosage form, such as: tablet, capsule, soft capsule, granule, drop pill, dispersible tablet, oral cavity disintegration tablet, pill etc.
14. according to claim 1-12 application of the described Chinese medicinal effective-part composition of any one in preparation Cure of depression medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110175605.0A CN102847050B (en) | 2011-06-28 | 2011-06-28 | A kind of Chinese medicinal effective-part composition being used for the treatment of depression |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110175605.0A CN102847050B (en) | 2011-06-28 | 2011-06-28 | A kind of Chinese medicinal effective-part composition being used for the treatment of depression |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102847050A true CN102847050A (en) | 2013-01-02 |
| CN102847050B CN102847050B (en) | 2016-01-27 |
Family
ID=47394295
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201110175605.0A Active CN102847050B (en) | 2011-06-28 | 2011-06-28 | A kind of Chinese medicinal effective-part composition being used for the treatment of depression |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102847050B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2802977C1 (en) * | 2022-11-20 | 2023-09-05 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Самарский государственный медицинский университет" Министерства здравоохранения Российской Федерации | Use of patulythrin as an antidepressant |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101322748A (en) * | 2007-06-15 | 2008-12-17 | 武汉健民中药工程有限责任公司 | Hypericum perforatum total flavones and formulation preparation and quality testing method |
| CN101816766A (en) * | 2010-01-27 | 2010-09-01 | 蔡光先 | Chinese medicinal composition for treating tristimania |
-
2011
- 2011-06-28 CN CN201110175605.0A patent/CN102847050B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101322748A (en) * | 2007-06-15 | 2008-12-17 | 武汉健民中药工程有限责任公司 | Hypericum perforatum total flavones and formulation preparation and quality testing method |
| CN101816766A (en) * | 2010-01-27 | 2010-09-01 | 蔡光先 | Chinese medicinal composition for treating tristimania |
Non-Patent Citations (2)
| Title |
|---|
| 唐瑛等: "中草药提取物的抗抑郁作用研究概况", 《湖南中医药导报》 * |
| 陈文星等: "姜黄素抗抑郁作用及其机理研究", 《中药新药与临床药理》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2802977C1 (en) * | 2022-11-20 | 2023-09-05 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Самарский государственный медицинский университет" Министерства здравоохранения Российской Федерации | Use of patulythrin as an antidepressant |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102847050B (en) | 2016-01-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101940616B (en) | Preparation method of effective part of Clinopodium chinense (Benth.) O. Kuntze for preventing and treating diabetes and medicine application thereof | |
| CN103536635A (en) | Preparation method of holothuria nobilis and application thereof in treatment of diabetes mellitus | |
| CN101480422A (en) | Tibetan oriental wormwood extract as well as preparation method and use thereof | |
| CN102228517B (en) | Plantain seed extract and application thereof | |
| Pokhrel et al. | A short glimpse on promising pharmacological effects of Begenia ciliata | |
| CN101816766B (en) | Chinese medicinal composition for treating tristimania | |
| CN103156869A (en) | Sanggenone C and sanggenone D extracted from morus plants and new medicine application of composition | |
| CN102743401B (en) | Application of panaxadiol saponins fraction in preparing medicine for preventing epilepsia | |
| Osigwe et al. | Antihyperglycemic studies on the leaf extract and active fractions of Newbouldia laevis (Bignoniaceae) | |
| CN102875615B (en) | Extraction method and application of falcate dolichos root or leaf glucoside A and total saponins of falcate dolichos root or leaf | |
| CN108434399A (en) | A kind of Chinese medicine composition and preparation method of anti-curing oncoma | |
| CN1803179B (en) | Traditional Chinese medicine composition and its preparation method and quality control method | |
| CN103585192A (en) | Preparation method and application of Aleuritopteris argentea Fee extract | |
| CN100594913C (en) | Medicine combination for curing diabetes and complication thereof and the preparing method and purpose | |
| CN102824480A (en) | Auxiliary blood sugar decreasing composite containing tibetan medicine edgeworthia gardneri and preparation method of composite | |
| CN102579530A (en) | Preparation method of aralia taibaiensis total saponin having diabetes mellitus resisting effect and medicament | |
| Sahu et al. | Development and evaluation of antidiabetic potential of polyherbal formulation in streptozotocin induced animal model | |
| CN102847050B (en) | A kind of Chinese medicinal effective-part composition being used for the treatment of depression | |
| CN101843669B (en) | Chinese medicinal effective-part composition for treating coronary heart diseases | |
| CN100355440C (en) | Compound Chinese medicinal preparation for treating type II diabetes and lowering blood sugar and its preparation method | |
| CN104547022A (en) | Traditional Chinese medicinal composition capable of clearing heat, moistening lung, relieving sore throat and detoxifying | |
| CN104523795A (en) | Application of cornua cervi pantotrichum glycopeptide composition in preparation of anti-anoxia drugs and health foods | |
| CN107951927A (en) | The extracting method of active material in medicine mulberry leaf | |
| CN104042928A (en) | Pharmaceutical composition for treating diabetes and its preparation method and use | |
| CN110448622B (en) | Medicine for treating heat type cold and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CB03 | Change of inventor or designer information | ||
| CB03 | Change of inventor or designer information |
Inventor after: Han Yuanshan Inventor after: Wang Yuhong Inventor before: Wang Yuhong Inventor before: Han Yuanshan |